{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:13:36Z","timestamp":1785870816007,"version":"3.56.0"},"reference-count":108,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive fat in the liver. An international consensus panel has recently proposed to rename the disease to metabolic dysfunction associated with fatty liver disease (MAFLD). The disease can range from simple steatosis (fat accumulation) to nonalcoholic steatohepatitis (NASH) which represents a severe form of NAFLD and is accompanied by inflammation, fibrosis, and hepatocyte damage in addition to significant steatosis. This review collates current knowledge of changes in human hepatic cytochrome P450 enzymes in NAFLD. While the expression of these enzymes is well studied in healthy volunteers, our understanding of the alterations of these proteins in NAFLD is limited. Much of the existing knowledge on the subject is derived from preclinical studies, and clinical translation of these findings is poor. Wherever available, the effect of NAFLD on these proteins in humans is debatable and currently lacks a consensus among different reports. Protein expression is an important in vitro physiological parameter controlling the pharmacokinetics of drugs and the last decade has seen a rise in the accurate estimation of these proteins for use with physiologically based pharmacokinetic (PBPK) modeling to predict drug pharmacokinetics in special populations. The application of label-free, mass spectrometry-based quantitative proteomics as a promising tool to study NAFLD-associated changes has also been discussed.<\/jats:p>","DOI":"10.3390\/ph13090222","type":"journal-article","created":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T06:06:22Z","timestamp":1598767582000},"page":"222","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3747-3894","authenticated-orcid":false,"given":"Rohitash","family":"Jamwal","sequence":"first","affiliation":[{"name":"Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Barlock","sequence":"additional","affiliation":[{"name":"Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.4254\/wjh.v7.i11.1450","article-title":"Non-alcoholic fatty liver disease in 2015","volume":"7","author":"Ahmed","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9488","DOI":"10.3748\/wjg.v22.i43.9488","article-title":"Nonalcoholic fatty liver disease\u2014A multisystem disease?","volume":"22","author":"Mikolasevic","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/hep.28584","article-title":"Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Lonardo","year":"2016","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","article-title":"Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis","volume":"24","author":"Leoni","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-16-0513","article-title":"Hepatic lipid accumulation: Cause and consequence of dysregulated glucoregulatory hormones","volume":"234","author":"Geisler","year":"2017","journal-title":"J. Endocrinol."},{"key":"ref_9","first-page":"S17","article-title":"Pathophysiology of nonalcoholic steatohepatitis","volume":"40","author":"McCullough","year":"2006","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/acs.molpharmaceut.8b00159","article-title":"Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver","volume":"15","author":"Jamwal","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: From steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7352","DOI":"10.3390\/ijms15057352","article-title":"Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)","volume":"15","author":"Takaki","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Brunt, E.M. (2016). Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010097"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cld.2015.10.005","article-title":"The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities","volume":"20","author":"Kalia","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"ref_20","first-page":"45","article-title":"Non-alcoholic fatty liver disease may develop in individuals with normal body mass index","volume":"25","author":"Margariti","year":"2012","journal-title":"Ann. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Anderson, E.L., Howe, L.D., Jones, H.E., Higgins, J.P., Lawlor, D.A., and Fraser, A. (2015). The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140908"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bush, H., Golabi, P., and Younossi, Z.M. (2017). Pediatric Non-Alcoholic Fatty Liver Disease. Children, 4.","DOI":"10.3390\/children4060048"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2016.0109","article-title":"Genetic predisposition in nonalcoholic fatty liver disease","volume":"23","author":"Sookoian","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/hmg\/ddy124","article-title":"NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects","volume":"27","author":"Sliz","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1038\/s41598-018-23453-9","article-title":"Lack of evidence supporting a role of TMC4-rs641738 missense variant-MBOAT7- intergenic downstream variant-in the Susceptibility to Nonalcoholic Fatty Liver Disease","volume":"8","author":"Sookoian","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"g4596","DOI":"10.1136\/bmj.g4596","article-title":"Non-alcoholic fatty liver disease","volume":"349","author":"Sattar","year":"2014","journal-title":"BMJ"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13244-011-0112-5","article-title":"Fatty liver deposition and sparing: A pictorial review","volume":"2","author":"Decarie","year":"2011","journal-title":"Insights Imaging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/hep.24268","article-title":"Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality","volume":"53","author":"Younossi","year":"2011","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/hep.24403","article-title":"Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: Two distinct concepts","volume":"53","author":"Angulo","year":"2011","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/hep.24347","article-title":"Misuse of scoring systems","volume":"54","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/138920012803341302","article-title":"Drug disposition in pathophysiological conditions","volume":"13","author":"Gandhi","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/hepr.12856","article-title":"Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus","volume":"47","author":"Sumida","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.metabol.2016.04.004","article-title":"Pharmacological management of nonalcoholic fatty liver disease","volume":"65","author":"Barb","year":"2016","journal-title":"Metabolism"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/jgh.12242","article-title":"Treatment of non-alcoholic fatty liver disease","volume":"28","author":"Takei","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/hep.28392","article-title":"Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice","volume":"63","author":"Marchesini","year":"2016","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Friedman","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/ajcn\/86.2.285","article-title":"Comparative review of diets for the metabolic syndrome: Implications for nonalcoholic fatty liver disease","volume":"86","author":"Zivkovic","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3945\/ajcn.2008.26720","article-title":"Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: Dysregulated enteroadipocyte axis as a novel feature of fatty liver","volume":"89","author":"Musso","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hep.23535","article-title":"Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease","volume":"51","author":"Abdelmalek","year":"2010","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1172\/JCI37385","article-title":"Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight\/obese humans","volume":"119","author":"Stanhope","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/liv.13270","article-title":"The therapeutic landscape of non-alcoholic steatohepatitis","volume":"37","author":"Perazzo","year":"2017","journal-title":"Liver Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_47","unstructured":"Surapaneni, D.Z.a.S. (2012). Drug Metabolizing Enzymes and Biotransformation Reactions. ADME-Enabling Technologies in Drug Design and Development, John Wiley & Sons, Inc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5507\/bp.2010.017","article-title":"Phase II drug metabolizing enzymes","volume":"154","author":"Jancova","year":"2010","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2613.2011.00793.x","article-title":"Pathology of the liver in obese and diabetic ob\/ob and db\/db mice fed a standard or high-calorie diet","volume":"92","author":"Paradis","year":"2011","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/dmd.113.055996","article-title":"Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models","volume":"42","author":"Canet","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00204-008-0312-z","article-title":"Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis","volume":"82","author":"Fisher","year":"2008","journal-title":"Arch. Toxicol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.gene.2004.06.015","article-title":"Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model","volume":"340","author":"Kim","year":"2004","journal-title":"Gene"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1248\/bpb.29.1634","article-title":"Changes in the expression of cytochromes P450 and nuclear receptors in the liver of genetically diabetic db\/db mice","volume":"29","author":"Yoshinari","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3727\/105221617X15093707969658","article-title":"Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights","volume":"18","author":"Stephenson","year":"2018","journal-title":"Gene Expr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2016.05.005","article-title":"A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer","volume":"65","author":"Asgharpour","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00795-013-0016-1","article-title":"A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma","volume":"46","author":"Fujii","year":"2013","journal-title":"Med. Mol. Morphol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/17425255.2017.1314461","article-title":"Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease","volume":"13","author":"Dietrich","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zhong, F., Zhou, X., Xu, J., and Gao, L. (2019). Rodent Models of Nonalcoholic Fatty Liver Disease. Digestion, 1\u201314.","DOI":"10.1159\/000501851"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cotox.2019.03.001","article-title":"Human in vitro models of nonalcoholic fatty liver disease","volume":"16","author":"Sturla","year":"2019","journal-title":"Curr. Opinion Toxicol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.cgh.2014.01.040","article-title":"Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis","volume":"12","author":"Ratziu","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","article-title":"Resveratrol does not benefit patients with nonalcoholic fatty liver disease","volume":"12","author":"Chachay","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cpt.1115","article-title":"Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and\/or Toxicity of Drugs: A White Paper From the International Transporter Consortium","volume":"104","author":"Evers","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD)\u2014Pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/03602532.2011.577781","article-title":"Drug metabolism alterations in nonalcoholic fatty liver disease","volume":"43","author":"Merrell","year":"2011","journal-title":"Drug Metab. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1152\/ajpgi.00074.2008","article-title":"Gene expression in human NAFLD","volume":"294","author":"Greco","year":"2008","journal-title":"Am. J. Physiol. Gastrointest Liver Physiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1124\/dmd.111.040592","article-title":"Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease","volume":"39","author":"Lake","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/dmd.115.065979","article-title":"CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease","volume":"43","author":"Woolsey","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/dmd.112.048439","article-title":"Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease","volume":"41","author":"Hardwick","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_71","first-page":"351","article-title":"Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease","volume":"20","author":"Kohjima","year":"2007","journal-title":"Int. J. Mol. Med."},{"key":"ref_72","first-page":"733","article-title":"Hepatic cytochrome P450 2E1 activity in nonalcoholic fatty liver disease","volume":"91","author":"Prompila","year":"2008","journal-title":"J. Med. Assoc. Thai."},{"key":"ref_73","first-page":"631","article-title":"Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease","volume":"16","author":"Nakamuta","year":"2005","journal-title":"Int. J. Mol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Baker, S.S., Baker, R.D., Liu, W., Nowak, N.J., and Zhu, L. (2010). Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009570"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2003.50095","article-title":"Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis","volume":"37","author":"Chalasani","year":"2003","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.hepres.2005.10.001","article-title":"Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients","volume":"34","author":"Orellana","year":"2006","journal-title":"Hepatol. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/hep.510270121","article-title":"Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis","volume":"27","author":"Weltman","year":"1998","journal-title":"Hepatology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0168-8278(00)80120-8","article-title":"Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases","volume":"33","author":"Niemela","year":"2000","journal-title":"J. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1124\/dmd.106.009670","article-title":"Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts","volume":"34","author":"Donato","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1053\/jhep.2003.50342","article-title":"CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease","volume":"38","author":"Emery","year":"2003","journal-title":"Hepatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/SLA.0b013e3181dbb572","article-title":"Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content","volume":"251","author":"Bell","year":"2010","journal-title":"Ann. Surg."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.tiv.2006.07.008","article-title":"Effects of steatosis on drug-metabolizing capability of primary human hepatocytes","volume":"21","author":"Donato","year":"2007","journal-title":"Toxicol. In Vitro"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.cgh.2006.12.021","article-title":"Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity","volume":"5","author":"Kolwankar","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jhep.2006.10.021","article-title":"Identification of a gene-pathway associated with non-alcoholic steatohepatitis","volume":"46","author":"Rubio","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s11695-010-0078-2","article-title":"Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease","volume":"20","author":"Stepanova","year":"2010","journal-title":"Obes. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1872-034X.2008.00399.x","article-title":"Gene expression profiling of non-alcoholic steatohepatitis using gene set enrichment analysis","volume":"38","author":"Yoneda","year":"2008","journal-title":"Hepatol. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.1013","article-title":"Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective","volume":"104","author":"Shebley","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.apsb.2016.04.004","article-title":"PBPK modeling and simulation in drug research and development","volume":"6","author":"Zhuang","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cpt.1699","article-title":"Quantitative Proteomics and Mechanistic Modeling of Transporter-Mediated Disposition in Nonalcoholic Fatty Liver Disease","volume":"107","author":"Vildhede","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/ijms15011026","article-title":"Evaluation of hepatic tissue blood flow using xenon computed tomography with fibrosis progression in nonalcoholic fatty liver disease: Comparison with chronic hepatitis C","volume":"15","author":"Shigefuku","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ar.20715","article-title":"Hepatic microcirculation in fatty liver disease","volume":"291","author":"Farrell","year":"2008","journal-title":"Anat. Rec. (Hoboken)"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.redox.2017.06.008","article-title":"Non-alcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers","volume":"13","author":"Anavi","year":"2017","journal-title":"Redox. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1148\/radiol.14132952","article-title":"Nonalcoholic fatty liver disease: Portal hypertension due to outflow block in patients without cirrhosis","volume":"274","author":"Hirooka","year":"2015","journal-title":"Radiology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00535-012-0581-4","article-title":"Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: Can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis?","volume":"47","author":"Shigefuku","year":"2012","journal-title":"J. Gastroenterol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hep.510310201","article-title":"Oxygen: Modulator of metabolic zonation and disease of the liver","volume":"31","author":"Jungermann","year":"2000","journal-title":"Hepatology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.redox.2017.01.012","article-title":"Metabolic zonation of the liver: The oxygen gradient revisited","volume":"11","author":"Kietzmann","year":"2017","journal-title":"Redox. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0306-3623(96)00183-8","article-title":"Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver","volume":"28","author":"Lindros","year":"1997","journal-title":"Gen. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/gut.33.1.92","article-title":"Estimation of total hepatic blood flow by duplex ultrasound","volume":"33","author":"Carlisle","year":"1992","journal-title":"Gut"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3748\/wjg.v24.i15.1601","article-title":"Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity","volume":"24","author":"Pirola","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-1-60761-444-9_18","article-title":"An overview of label-free quantitation methods in proteomics by mass spectrometry","volume":"604","author":"Wong","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1208\/s12248-014-9712-6","article-title":"Choice of LC-MS methods for the absolute quantification of drug-metabolizing enzymes and transporters in human tissue: A comparative cost analysis","volume":"17","author":"Achour","year":"2015","journal-title":"AAPS J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1021\/acs.jproteome.7b00505","article-title":"Multiplex and Label-Free Relative Quantification Approach for Studying Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes Using SWATH-MS","volume":"16","author":"Jamwal","year":"2017","journal-title":"J. Proteome Res."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Gillet, L.C., Navarro, P., Tate, S., Rost, H., Selevsek, N., Reiter, L., Bonner, R., and Aebersold, R. (2012). Targeted data extraction of the MS\/MS spectra generated by data-independent acquisition: A new concept for consistent and accurate proteome analysis. Mol. Cell Proteomics, 11.","DOI":"10.1074\/mcp.O111.016717"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"140031","DOI":"10.1038\/sdata.2014.31","article-title":"A repository of assays to quantify 10,000 human proteins by SWATH-MS","volume":"1","author":"Rosenberger","year":"2014","journal-title":"Sci. Data"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/nbt.3685","article-title":"A multicenter study benchmarks software tools for label-free proteome quantification","volume":"34","author":"Navarro","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1074\/mcp.M113.037309","article-title":"A \u201cproteomic ruler\u201d for protein copy number and concentration estimation without spike-in standards","volume":"13","author":"Wisniewski","year":"2014","journal-title":"Mol. Cell Proteomics"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/9\/222\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:04:39Z","timestamp":1760177079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/9\/222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,29]]},"references-count":108,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["ph13090222"],"URL":"https:\/\/doi.org\/10.3390\/ph13090222","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,29]]}}}